With the new program, patients using Amazon Pharmacy will no longer have to search for and manually enter coupons from the three largest insulin makers, Novo Nordisk, Eli Lilly, and Sanofi, to lower the cost of their insulin to as little as $35 for a month’s supply, the company said.

Amazon Pharmacy automates discounts to help insulin patients get pledged prices

We remain positive about Sanofi India on the back of pure domestic play, strong balance sheet and reasonable valuation.

Sanofi India Q2 Results Review - Margins Remain Resilient Despite NLEM Impact: Nirmal Bang

Sanofi India Standalone June 2023 Net Sales at Rs 706.10 crore, up 0.97% Y-o-Y

The company said Dupixent is the first biologic medicine for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies.

Sanofi India gets marketing nod for atopic dermatitis treatment medication

Sanofi, one of the top global vaccine makers, has stated that the current mRNA technology used in COVID-19 vaccines is not effective against influenza. The company is working on a next-generation flu shot based on mRNA, which showed a strong immune response against A strains but not against less pre…

Sanofi says it’s back to the drawing board on mRNA flu vaccines

Ahmedabad-based pharmaceutical company CORONA Remedies has acquired the muscle relaxant brand Myoril from Sanofi India for Rs234 crore. The acquisition includes Myoril and its extensions. This acquisition comes after Corona’s previous acquisitions of drug brands from GlaxoSmithKline and Abbott India…

CORONA remedies buys Sanofi India’s ortho brand Myoril

Corona Remedies acquires muscle relaxant brand Myoril from Sanofi, marking its largest acquisition. With a strong presence in western and southern India, Corona is set to expand its market penetration and coverage in the orthopaedics and physician space.

Corona Remedies acquires Myoril brand from Sanofi for ₹234 cr

Equitas Small Finance Bank, Birla Corporation, and Sanofi India were the top new small-cap picks by Indian mutual funds and portfolio management scheme (PMS) managers in May. Equitas SFB was selected by 9 mutual funds, 10 PMS, 13 unit-linked insurance plans, and one alternative investment fund. Othe…

Red-hot favourites! MF & PMS managers handpick 10 new smallcaps

Stocks In Focus | DRL, Hindalco, Novartis, Sanofi India And More | BQ Prime William O Neil India’s Mayuresh Joshi shares his views on #DRL, #Hindalco, #Novartis and other buzzing stocks in trade today.

Stocks In Focus | DRL, Hindalco, Novartis, Sanofi India And More | BQ Prime

None of the PSU stocks delivered a dividend of more than Rs 100 in the last one year. Coal India was the sole PSU stock with a dividend yield of 10 per cent or more.

TCS, Hero MotoCorp, Sanofi, 4 others paid up to Rs 570 dividend in a year

The company has outlined an ’India for India strategy, where it will focus on diabetes, consumer health, a combination of product innovation, supply localisation, and strategic partnerships, along with an overhaul of its go-to-market strategy.

Sanofi reinvigorates India business, with eye on higher growth

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced and in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Not a good time to consider, stock is in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Sanofi India Limited is engaged in the manufacture and sale of pharmaceutical products.

Sanofi India Ltd